Does the media refer more to TEVA or ELAN?

In the previous week, Elanco Animal Health had 4 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 12 mentions for Elanco Animal Health and 8 mentions for Teva Pharmaceutical Industries. Elanco Animal Health's average media sentiment score of 1.32 beat Teva Pharmaceutical Industries' score of 0.57 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or ONC?

In the previous week, Elanco Animal Health had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for Elanco Animal Health and 3 mentions for BeOne Medicines. Elanco Animal Health's average media sentiment score of 1.32 beat BeOne Medicines' score of 0.63 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RPRX or ELAN?

In the previous week, Elanco Animal Health had 5 more articles in the media than Royalty Pharma. MarketBeat recorded 12 mentions for Elanco Animal Health and 7 mentions for Royalty Pharma. Elanco Animal Health's average media sentiment score of 1.32 beat Royalty Pharma's score of 0.98 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZTS or ELAN?

In the previous week, Zoetis had 28 more articles in the media than Elanco Animal Health. MarketBeat recorded 40 mentions for Zoetis and 12 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.32 beat Zoetis' score of 1.22 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 33 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Positive Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VTRS or ELAN?

In the previous week, Elanco Animal Health had 11 more articles in the media than Viatris. MarketBeat recorded 12 mentions for Elanco Animal Health and 1 mentions for Viatris. Elanco Animal Health's average media sentiment score of 1.32 beat Viatris' score of 0.50 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Elanco Animal Health (ELAN) Competitors

$23.47 -1.03 (-4.20%)

Closing price 08/20/2026 03:58 PM Eastern

Extended Trading

$23.94 +0.47 (+2.00%)

As of 08:41 AM Eastern

Compare

ELAN vs. TEVA, ONC, RPRX, ZTS, and VTRS

Should you buy Elanco Animal Health stock or one of its competitors? Elanco Animal Health's main competitors and comparable companies include Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), Zoetis (ZTS), and Viatris (VTRS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Elanco Animal Health compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and Elanco Animal Health (NYSE:ELAN) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, Elanco Animal Health had 4 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 12 mentions for Elanco Animal Health and 8 mentions for Teva Pharmaceutical Industries. Elanco Animal Health's average media sentiment score of 1.32 beat Teva Pharmaceutical Industries' score of 0.57 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries presently has a consensus price target of $42.22, indicating a potential upside of 14.80%. Elanco Animal Health has a consensus price target of $29.09, indicating a potential upside of 23.95%. Given Elanco Animal Health's higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Teva Pharmaceutical Industries has a net margin of 4.08% compared to Elanco Animal Health's net margin of -3.96%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%
Elanco Animal Health	-3.96%	8.13%	3.99%

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.48	$1.41B	$0.60	61.30
Elanco Animal Health	$5.02B	2.34	-$232M	-$0.41	N/A

Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.

How does Elanco Animal Health compare to BeOne Medicines?

Elanco Animal Health (NYSE:ELAN) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BeOne Medicines has a net margin of 10.70% compared to Elanco Animal Health's net margin of -3.96%. BeOne Medicines' return on equity of 14.23% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
BeOne Medicines	10.70%	14.23%	7.82%

BeOne Medicines has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$5.02B	2.34	-$232M	-$0.41	N/A
BeOne Medicines	$5.34B	7.59	$286.93M	$5.68	64.99

Elanco Animal Health has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

In the previous week, Elanco Animal Health had 9 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for Elanco Animal Health and 3 mentions for BeOne Medicines. Elanco Animal Health's average media sentiment score of 1.32 beat BeOne Medicines' score of 0.63 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elanco Animal Health currently has a consensus price target of $29.09, indicating a potential upside of 23.95%. BeOne Medicines has a consensus price target of $402.14, indicating a potential upside of 8.93%. Given Elanco Animal Health's higher probable upside, equities analysts plainly believe Elanco Animal Health is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

BeOne Medicines beats Elanco Animal Health on 12 of the 17 factors compared between the two stocks.

How does Elanco Animal Health compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Elanco Animal Health (NYSE:ELAN) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Royalty Pharma has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.54B	13.74	$770.95M	$1.45	41.78
Elanco Animal Health	$5.02B	2.34	-$232M	-$0.41	N/A

Royalty Pharma presently has a consensus price target of $60.86, suggesting a potential upside of 0.46%. Elanco Animal Health has a consensus price target of $29.09, suggesting a potential upside of 23.95%. Given Elanco Animal Health's higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Elanco Animal Health had 5 more articles in the media than Royalty Pharma. MarketBeat recorded 12 mentions for Elanco Animal Health and 7 mentions for Royalty Pharma. Elanco Animal Health's average media sentiment score of 1.32 beat Royalty Pharma's score of 0.98 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has a net margin of 32.14% compared to Elanco Animal Health's net margin of -3.96%. Royalty Pharma's return on equity of 30.01% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Elanco Animal Health	-3.96%	8.13%	3.99%

54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Royalty Pharma has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market.

Summary

Royalty Pharma beats Elanco Animal Health on 9 of the 17 factors compared between the two stocks.

How does Elanco Animal Health compare to Zoetis?

Zoetis (NYSE:ZTS) and Elanco Animal Health (NYSE:ELAN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

In the previous week, Zoetis had 28 more articles in the media than Elanco Animal Health. MarketBeat recorded 40 mentions for Zoetis and 12 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 1.32 beat Zoetis' score of 1.22 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	33 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Positive
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has a net margin of 27.49% compared to Elanco Animal Health's net margin of -3.96%. Zoetis' return on equity of 74.89% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.49%	74.89%	18.59%
Elanco Animal Health	-3.96%	8.13%	3.99%

Zoetis currently has a consensus target price of $109.23, suggesting a potential upside of 45.39%. Elanco Animal Health has a consensus target price of $29.09, suggesting a potential upside of 23.95%. Given Zoetis' higher possible upside, analysts plainly believe Zoetis is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

92.8% of Zoetis shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zoetis has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.53B	3.26	$2.67B	$6.07	12.38
Elanco Animal Health	$5.02B	2.34	-$232M	-$0.41	N/A

Zoetis has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

Summary

Zoetis beats Elanco Animal Health on 10 of the 17 factors compared between the two stocks.

How does Elanco Animal Health compare to Viatris?

Viatris (NASDAQ:VTRS) and Elanco Animal Health (NYSE:ELAN) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

Viatris currently has a consensus price target of $17.50, indicating a potential upside of 8.56%. Elanco Animal Health has a consensus price target of $29.09, indicating a potential upside of 23.95%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts clearly believe Elanco Animal Health is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Elanco Animal Health has lower revenue, but higher earnings than Viatris. Elanco Animal Health is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.74B	1.26	-$3.51B	-$0.36	N/A
Elanco Animal Health	$5.02B	2.34	-$232M	-$0.41	N/A

In the previous week, Elanco Animal Health had 11 more articles in the media than Viatris. MarketBeat recorded 12 mentions for Elanco Animal Health and 1 mentions for Viatris. Elanco Animal Health's average media sentiment score of 1.32 beat Viatris' score of 0.50 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris has a net margin of -2.79% compared to Elanco Animal Health's net margin of -3.96%. Viatris' return on equity of 20.02% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.79%	20.02%	8.02%
Elanco Animal Health	-3.96%	8.13%	3.99%

79.9% of Viatris shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Elanco Animal Health beats Viatris on 11 of the 17 factors compared between the two stocks.

Get Elanco Animal Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELAN vs. The Competition

Export

Metric	Elanco Animal Health	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$12.24B	$12.62B	$7.35B	$24.24B
Dividend Yield	N/A	2.65%	2.54%	3.71%
P/E Ratio	-57.24	779.90	268.95	29.98
Price / Sales	2.34	787.93	578.09	19.97
Price / Cash	10.56	94.24	78.13	32.31
Price / Book	1.78	11.90	13.01	6.75
Net Income	-$232M	$2.80B	$3.46B	$1.07B
7 Day Performance	-0.71%	0.60%	0.96%	-1.29%
1 Month Performance	-7.80%	1.52%	3.84%	1.64%
1 Year Performance	34.08%	6.76%	26.46%	17.29%

Elanco Animal Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELAN Elanco Animal Health	4.2964 of 5 stars	$23.47 -4.2%	$29.09 +23.9%	+34.6%	$12.24B	$5.02B	N/A	9,400	Positive News
TEVA Teva Pharmaceutical Industries	3.5003 of 5 stars	$36.04 +1.9%	$42.00 +16.5%	+109.0%	$42.11B	$17.31B	60.07	33,950	Positive News
ONC BeOne Medicines	3.8342 of 5 stars	$359.00 +3.1%	$402.14 +12.0%	+19.3%	$38.21B	$5.34B	63.20	12,000	High Trading Volume
RPRX Royalty Pharma	4.148 of 5 stars	$57.97 +2.1%	$60.86 +5.0%	+64.3%	$32.69B	$2.38B	39.98	80	Insider Trade
ZTS Zoetis	4.7338 of 5 stars	$74.62 +2.7%	$110.92 +48.6%	-52.1%	$30.46B	$9.47B	12.29	14,500	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ELAN) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elanco Animal Health (ELAN) Competitors

ELAN vs. TEVA, ONC, RPRX, ZTS, and VTRS

How does Elanco Animal Health compare to Teva Pharmaceutical Industries?

Summary

How does Elanco Animal Health compare to BeOne Medicines?

Summary

How does Elanco Animal Health compare to Royalty Pharma?

Summary

How does Elanco Animal Health compare to Zoetis?

Summary

How does Elanco Animal Health compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAN vs. The Competition

Elanco Animal Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elanco Animal Health (ELAN) Competitors

ELAN vs. TEVA, ONC, RPRX, ZTS, and VTRS

How does Elanco Animal Health compare to Teva Pharmaceutical Industries?

Does the media refer more to TEVA or ELAN?

Do analysts prefer TEVA or ELAN?

Is TEVA or ELAN more profitable?

Do institutionals and insiders believe in TEVA or ELAN?

Which has higher earnings and valuation, TEVA or ELAN?

Which has more volatility and risk, TEVA or ELAN?

Summary

How does Elanco Animal Health compare to BeOne Medicines?

Do institutionals and insiders hold more shares of ELAN or ONC?

Is ELAN or ONC more profitable?

Which has higher valuation & earnings, ELAN or ONC?

Which has more risk & volatility, ELAN or ONC?

Does the media favor ELAN or ONC?

Do analysts recommend ELAN or ONC?

Summary

How does Elanco Animal Health compare to Royalty Pharma?

Which has stronger valuation and earnings, RPRX or ELAN?

Do analysts rate RPRX or ELAN?

Does the media refer more to RPRX or ELAN?

Is RPRX or ELAN more profitable?

Do institutionals & insiders have more ownership in RPRX or ELAN?

Which has more risk & volatility, RPRX or ELAN?

Summary

How does Elanco Animal Health compare to Zoetis?

Does the media refer more to ZTS or ELAN?

Is ZTS or ELAN more profitable?

Do analysts rate ZTS or ELAN?

Do institutionals and insiders have more ownership in ZTS or ELAN?

Which has better earnings & valuation, ZTS or ELAN?

Which has more risk and volatility, ZTS or ELAN?

Summary

How does Elanco Animal Health compare to Viatris?

Which has more volatility and risk, VTRS or ELAN?

Do analysts rate VTRS or ELAN?

Which has better valuation & earnings, VTRS or ELAN?

Does the media favor VTRS or ELAN?

Is VTRS or ELAN more profitable?

Do institutionals & insiders have more ownership in VTRS or ELAN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELAN vs. The Competition

Elanco Animal Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools